Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

TCMCB07

Phase 2Small molecule

TCMCB07 is one of 34 small molecule programs targeting Weight loss. It is currently in Phase 2.

1

Indications

2

Total Trials

1

Active Trials

33

Competitors

Pipeline

Status by Indication[3][1]

Indication

Weight LossRecruiting

Weight LossPhase 2

Recruiting

Competition

Competitive Landscape

35 competitors in Weight Loss

#DrugCompanyPhaseTrials

Victoza

Ozempic

Farxiga

Glucophage

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Topamax

Xifaxan

Invokana

Megace

Bristol-Myers Squibb

Versed

CConrado Roberto Hoffmann Filho

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Weight Loss

NCT06937177

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects

Completed·EEndevica Bio·Phase 1·NCT05529849·76 enrolled

Weight loss1 trial

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Recruiting·EEndevica Bio·Phase 2·NCT06937177·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TCMCB07. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TCMCB07 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TCMCB07. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Endevica Bio company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEndevica Bio

Related News